Pfizer Inc. (PFE)
NYSE·Healthcare·Drug Manufacturers - General
$26.46
-1.21%
Mkt Cap $156.54B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 3, 2026 | $16.85B | $17.56B | +4.20% | $0.57 | $0.66 | +16.40% | — | — |
| Q4 2025 Nov 4, 2025 | $16.50B | $16.65B | +0.94% | $0.63 | $0.87 | +37.44% | — | — |
| Q3 2025 Aug 5, 2025 | $13.56B | $14.65B | +8.06% | $0.58 | $0.78 | +34.48% | — | — |
| Q2 2025 Apr 29, 2025 | $13.92B | $13.71B | -1.47% | $0.67 | $0.92 | +38.14% | — | — |
| Q1 2025 Feb 4, 2025 | $17.35B | $17.76B | +2.38% | $0.47 | $0.63 | +33.59% | — | — |
| Q4 2024 Oct 29, 2024 | $14.92B | $17.70B | +18.63% | $0.61 | $1.06 | +72.64% | — | — |
| Q3 2024 Jul 30, 2024 | $12.96B | $13.28B | +2.48% | $0.46 | $0.60 | +31.00% | — | — |
| Q2 2024 May 1, 2024 | $13.87B | $14.88B | +7.25% | $0.52 | $0.82 | +58.91% | — | — |
| Q1 2024 Jan 30, 2024 | $14.25B | $14.25B | +0.00% | -$0.19 | $0.10 | +152.63% | — | — |
| Q4 2023 Oct 31, 2023 | $12.72B | $13.23B | +4.00% | -$0.32 | -$0.17 | +46.88% | — | — |
| Q3 2023 Aug 1, 2023 | $12.08B | $12.73B | +5.38% | $0.56 | $0.67 | +19.64% | — | — |
| Q2 2023 May 2, 2023 | $16.59B | $18.28B | +10.18% | $0.98 | $1.23 | +25.51% | — | — |
| Q1 2023 Jan 31, 2023 | $24.38B | $24.29B | -0.38% | $1.05 | $1.14 | +8.57% | — | — |
| Q4 2022 Nov 1, 2022 | $21.07B | $22.64B | +7.43% | $1.39 | $1.78 | +28.06% | — | — |
| Q3 2022 Jul 28, 2022 | $25.49B | $27.74B | +8.85% | $1.78 | $2.04 | +14.61% | — | — |
| Q2 2022 May 3, 2022 | $24.10B | $25.66B | +6.48% | $1.47 | $1.67 | +13.61% | — | — |
| Q1 2022 Feb 8, 2022 | $24.16B | $23.84B | -1.32% | $0.85 | $1.08 | +27.06% | — | — |
| Q4 2021 Nov 2, 2021 | $22.38B | $24.09B | +7.65% | $1.09 | $1.34 | +22.94% | — | — |
| Q3 2021 Jul 28, 2021 | $22.87B | $18.98B | -17.03% | $0.97 | $1.07 | +10.31% | — | — |
| Q2 2021 May 4, 2021 | $13.55B | $14.58B | +7.61% | $0.77 | $0.93 | +20.78% | — | — |